The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 27, 1994
Filed:
Jun. 19, 1992
Susan L Bernhard, Menlo Park, CA (US);
Marc D Better, Los Angeles, CA (US);
Steve F Carroll, Walnut Creek, CA (US);
Julie A Lane, Castro Valley, CA (US);
Xoma Corporation, Berkeley, CA (US);
Abstract
The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins and analogs thereof having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. Preferred analogs according to the present invention are analogs of Type I ribosome-inactivating proteins (1) having a cysteine available for intermolecular disulfide bonding located at an amino acid position corresponding to a position not naturally available for intermolecular disulfide bonding in the Type I ribosome-inactivating protein and corresponding to a position on the surface of ricin A-chain in its natural conformation and (2) retaining ribosome-inactivating activity of the Type I ribosome-inactivating protein. The RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents and, more specifically, as components of immunotoxins. Cytotoxic agents according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component, and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.